immuno-oncology

News

Replimune's RP1 immunotherapy for melanoma clears advisory committee vote by 10 to three, despite FDA concerns about the design of the IGNYTE study.

News

Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.

News

A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.

News

Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.

Market Access

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

News

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.